search

Active clinical trials for "Fatty Liver"

Results 301-310 of 1375

Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease...

Esophageal VaricesNon-alcoholic Fatty Liver1 more

Non-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection, immune-mediated, or medication related which can lead to fibrosis and later-on, cirrhosis. Over the last years NAFLD related liver cirrhosis has become the commonest cause of chronic liver disease worldwide. Portal hypertension is the major complication caused by increased splanchnic blood flow which leads to development of oesophageal varices (OV). Almost all of the patients with portal hypertension can develop OV sometime in their life and one third of those will bleed, hence identifying the presence of OV is a an important aspect of diagnostic workup of these patients with portal hypertension. Upper digestive camera test/endoscopy is the only means to diagnose and grade OV but endoscopy is an invasive procedure and its cost effectiveness for screening is also questionable. These limitations and the ever-increasing workload on endoscopy units has led many researchers to identify some parameters that can non-invasively diagnose OV. Researchers have proposed use of platelet count/spleen diameter ratio, liver stiffness on Fibroscan among many non-invasive tools to predict OV in patients with portal hypertension with success. Recently criteria proposed in Baveno VI conference, (Baveno-IV Criteria) recommended that screening endoscopy can be avoided in patients with compensated advanced chronic liver disease (cACLD) with liver stiffness measurement (LSM) less than 20 kPa and a platelet count more than than 150,000/μL with an expanded Baveno-IV criteria suggesting platelet count >110 × 109 cells/L and LSM <25 kPa can spare even more endoscopies with a risk of missing varices needing treatment (VNT) being minimal.

Recruiting9 enrollment criteria

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Non-alcoholic SteatohepatitisHepatic Impairment

The purpose of this study is to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

Not yet recruiting8 enrollment criteria

The Visceral Adiposity Measurement and Observation Study

HIVHIV-Infections17 more

The Visceral Adiposity Measurement and Observation Study

Recruiting16 enrollment criteria

Prospective Cohort Study in Patients With NAFLD

Non-alcoholic Fatty Liver Disease

To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.

Recruiting6 enrollment criteria

Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

NAFLD

The investigators will conduct a proof-of-principle deep phenotyping 4-weeks caloric restriction intervention study in low birth weight (LBW) subjects with NAFLD and normal birth weight (NBW) controls. Furthermore, the investigators will provide extended in-depth mechanistic insight into the role of impaired subcutaneous adipose tissue (SAT) expandability in ectopic fat deposition in LBW subjects in LBW individuals with and without NAFLD.

Not yet recruiting10 enrollment criteria

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver...

Fatty Liver DiseaseFatty Liver

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

Not yet recruiting14 enrollment criteria

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Hepatic SteatosisNAFLD1 more

Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group.

Not yet recruiting15 enrollment criteria

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome...

Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus

Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators). Twelve eligible subjects with NAFLD will be randomly assigned to receive either active fecal microbiota transplantation in orally administered capsules or Placebo capsules and dosed twice weekly for 12 weeks. .

Not yet recruiting20 enrollment criteria

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis With Liver Fibrosis

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).

Active5 enrollment criteria

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects...

Non-alcoholic Steatohepatitis (NASH)

This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses

Active42 enrollment criteria
1...303132...138

Need Help? Contact our team!


We'll reach out to this number within 24 hrs